Nicox's Jerry St. Peter nominated to TFOS Corporate Advisory Board

Nicox's Jerry St. Peter nominated to TFOS Corporate Advisory Board

...................................

October 16, 2014.

Sophia Antipolis, France.

Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced that Jerry St. Peter, Executive Vice President and General Manager of Nicox's US subsidiary Nicox Inc., has been nominated to the Corporate Advisory Board of the Tear Film & Ocular Surface Society (TFOS). TFOS is an international, non-profit eye health organization dedicated to advancing research and education related to the scientific field of the surface of the eye. 

Mr St. Peter said: "TFOS brings together many of the world's leading experts on ocular surface disease and plays an important role in advancing knowledge and understanding of front-of-the-eye disorders. It is a great honor for me to join the Corporate Advisory Board and collaborate to promote their mission. I am particularly eager to learn the conclusions and recommendations of the upcoming Dry Eye WorkShop II (DEWS II). This initiative will update the definition, classification and diagnosis of dry eye disease, critically assess the etiology, mechanism, distribution and global impact of this disorder, and address its management and therapy."

Mr St. Peter joined Nicox in March 2012 to build and lead the Group's US commercial team. Before joining Nicox, he served as Senior Vice President, Ophthalmology Business Unit at Inspire Pharmaceuticals, Inc, an ophthalmology-focused company acquired by Merck & Co. in May 2011. Mr St. Peter has more than 25 years of executive leadership experience within specialty pharmaceuticals and medical diagnostics.

About the Tear Film & Ocular Surface Society

Founded in 2000, TFOS is a world leader in eye health education and is dedicated to advancing the research, literacy and educational aspects of the scientific field of the ocular surface and tear film. The TFOS network includes basic scientists, academic clinicians and industry representatives originating from more than 80 countries. The Society has published The TFOS International Dry Eye Workshop (DEWS 2007), The TFOS International Report on Meibomian Gland Dysfunction (MGD 2011), the TFOS International Workshop on Contact Lens Discomfort (CLDW 2013) and is about to launch the sequel to the original Dry Eye Workshop, DEWS II. More information about TFOS and these reports are available at www.TearFilm.org. 

...................................

About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an emerging international company focused on the ophthalmic market. With a heritage of innovative R&D, business development and commercial expertise, the Nicox team is building a diversified portfolio of therapies and diagnostic tools that can help people to enhance their sight. The Company's commercial portfolio and near-term pipeline already include several innovative diagnostic tests intended for eye care professionals, as well as a range of eye care products. Nicox's key proprietary asset in ophthalmology is VESNEO (latanoprostene bunod), a novel compound based on Nicox's proprietary nitric oxide (NO)-donating R&D platform, currently in Phase 3 clinical development in collaboration with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Further NO-donors are under development, notably through partners.

Nicox is headquartered in France, with research capabilities in Italy, a growing commercial infrastructure in North America and in the major European markets and an expanding international presence through partners. Nicox S.A. is listed on Euronext Paris (Compartment B: Mid Caps). For more information on Nicox or its products please visit www.nicox.com.

...................................

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 4^th chapter of the "Document de référence, rapport financier annuel et rapport de gestion 2013" filed with the French Autorité des Marchés Financiers (AMF) on April 2^nd, 2014, in the "Rapport semestriel financier et d'activité au 30 juin 2014" and in the 5^th chapter of the "Actualisation du Document de Référence 2013" filed on September 30, 2014 (D. 14-0271-A01), available on Nicox's website (www.nicox.com).

...................................

Contacts